In the COURSE phase 2a study of the biologic tezepelumab versus placebo in chronic obstructive pulmonary disease (COPD), Dave Singh (Manchester University NHS Foundation Trust, Manchester, UK) and colleagues enrolled 333 patients aged 40–80 years with moderate to very severe COPD and at least two moderate or severe exacerbations in the past year. The researchers randomly assigned 165 patients to subcutaneous tezepelumab 420 mg every 4 weeks for 52 weeks, and 168 to matched placebo. The interventions were add-on treatment to existing triple inhaled maintenance therapy (ie, inhaled corticosteroids, long-acting β-agonists [LABA], and long-acting muscarinic antagonists [LAMA]).